John Martin Lee, MD
Nephrology · Tupelo, MSNPI 1205806155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Fresenius USA Marketing, Inc.$727
- Otsuka America Pharmaceutical, Inc.$605
- Bayer$463
- Amgen$425
- Mallinckrodt Hospital Products Inc.$417
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,22396%
- Education$2584%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,257 |
| Fresenius USA Marketing, Inc. | 38 | $727 |
| Otsuka America Pharmaceutical, Inc. | 28 | $605 |
| Bayer | 27 | $463 |
| Amgen(2 entities) | 23 | $425 |
| Mallinckrodt Hospital Products Inc. | 24 | $417 |
| Akebia Therapeutics Inc | 21 | $394 |
| Vifor Pharma, Inc. | 20 | $376 |
| OPKO Pharmaceuticals, LLC | 21 | $332 |
| Travere Therapeutics, Inc. | 17 | $295 |
| Novartis | 12 | $255 |
| GSK | 7 | $150 |
| Calliditas Therapeutics US Inc. | 5 | $88 |
| Lilly USA, LLC | 5 | $84 |
| Boehringer Ingelheim | 5 | $75 |
| Novo Nordisk | 5 | $71 |
| Nxstage Medical, Inc. | 1 | $70 |
| Daiichi Sankyo Inc. | 4 | $69 |
| Aurinia Pharma U.S., Inc. | 3 | $64 |
| Ardelyx, Inc. | 3 | $52 |
| Mallinckrodt Enterprises LLC | 3 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Abbott | 1 | $14 |
How this compares
$6,481 in reported general payments places this provider in the 90th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 155 | $121,566 |
| JardianceEmpagliflozin | 104 | $77,859 |
| VelphoroSucroferric Oxyhydroxide | 16 | $31,110 |
| AuryxiaFerric Citrate | 17 | $18,931 |
| Sevelamer Carbonate | 75 | $10,277 |
| Lanthanum Carbonate | 16 | $9,450 |
| Torsemide | 194 | $2,934 |
| Calcium Acetate | 37 | $1,683 |
| Cinacalcet Hcl | 16 | $1,615 |
| Losartan Potassium | 245 | $1,508 |
| Carvedilol | 132 | $670 |
| Spironolactone | 58 | $419 |
| Metolazone | 14 | $395 |
| Olmesartan Medoxomil | 40 | $382 |
| Metoprolol Succinate | 33 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,257 | $121,566155 claims |
| Boehringer IngelheimJardiance | $75 | $77,859104 claims |
| Fresenius USA Marketing, Inc.Velphoro | $727 | $31,11016 claims |
| Akebia Therapeutics IncAuryxia | $394 | $18,93117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Tupelo
- Thomas WooldridgeTupelo$8K
- Morris HamiltonTupelo$6K
- John ElliottTupelo$5K
- Christopher MillerTupelo$4K
- Tzonko MilevTupelo$4K
- Amita MaibamTupelo$4K
- Marcus BrittonTupelo$4K
- Calvin BakerTupelo$2K
- Shanti ParkashTupelo$2K
- Mohit AhujaFlowood$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.